
FDA Panel to Review Popular Injectable Peptides Amid Safety Concerns
The FDA's Pharmacy Compounding Advisory Committee meets Thursday for two days to recommend on allowing compounding pharmacies to make popular injectable peptides like TB-500 and BPC-157. This decision is critical amidst safety concerns, lack of large-scale human trials, and industry pressure to lift current restrictions.
















